Valuation: Milestone Pharmaceuticals Inc.

Market Cap 146M 126M 118M 108M 203M 13.89B 206M 1.39B 544M 6.95B 547M 535M 23.2B P/E 2026 *
-1.28x
P/E 2027 * -1.26x
Enterprise Value 146M 126M 118M 108M 203M 13.89B 206M 1.39B 544M 6.95B 547M 535M 23.2B EV / Sales 2026 *
36.6x
EV / Sales 2027 * 6.35x
Free-Float
99.3%
Yield 2026 *
-
Yield 2027 * -
1 day-4.89%
1 week-9.32%
Current month-3.60%
1 month-16.41%
3 months-37.79%
6 months-37.06%
Current year-47.03%
1 week 1.04
Extreme 1.04
1.29
1 month 1.01
Extreme 1.01
1.32
Current year 1
Extreme 1
2.34
1 year 1
Extreme 1
3.06
3 years 0.63
Extreme 0.6254
3.52
5 years 0.63
Extreme 0.6254
9.85
10 years 0
Extreme 0
27.95
Manager TitleAgeSince
Chief Executive Officer 59 2017-03-06
Director of Finance/CFO 53 2019-09-08
Compliance Officer 48 2026-02-09
Director TitleAgeSince
Director/Board Member 59 2017-06-30
Director/Board Member 60 2019-03-31
Director/Board Member 67 2020-09-30
Date Insider Type Main position Quantity % Market Cap.
6/10/26 Free

Director

77,000 0.0618%
2/2/26 Free

Chief Operating Officer

204,000 0.2395%
2/2/26 Free

Chief Executive Officer

679,000 0.7972%
Change 5-day change 1-year change 3-year change Capi.($)
-4.89%-9.32%-38.51%-66.25% 153M
+2.07%+13.76%+65.44%+106.53% 70.1B
-0.87%+0.08%+36.96%+65.91% 54.93B
-4.50%-4.69%+2.82%+463.22% 28.89B
-1.01%-1.35%+46.79%+6.32% 23.9B
-0.67%+1.02%-18.32%-13.84% 23.3B
-0.59%+7.88%+40.87%-20.56% 18.77B
+0.35%+12.02%+257.19%+466.50% 18.41B
-1.24%-3.89%+19.58%+610.27% 16.1B
+0.46%-3.05%+31.49%+135.18% 12.48B
Average -1.10%+3.30%+44.43%+175.33% 26.7B
Weighted average by Cap. -0.35%+3.97%+50.91%+164.78%

Financials

2026 *2027 *
Net sales 3.98M 3.45M 3.24M 2.95M 5.55M 380M 5.64M 38.11M 14.88M 190M 14.95M 14.63M 635M 22.91M 19.86M 18.62M 16.97M 31.94M 2.19B 32.45M 219M 85.58M 1.09B 86.01M 84.15M 3.65B
Net income -115M -100M -93.74M -85.48M -161M -11.01B -163M -1.1B -431M -5.51B -433M -424M -18.39B -128M -111M -104M -95.09M -179M -12.25B -182M -1.23B -479M -6.13B -482M -471M -20.45B
Net Debt - -
Logo Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Employees
38
Date Price Change Volume
26-08-13 US$1.070 -4.89% 2,666,546
26-08-12 US$1.125 -11.42% 5,785,634
26-08-11 US$1.270 +0.79% 1,383,799
26-08-10 US$1.260 +3.28% 1,626,983
26-08-07 US$1.220 +3.39% 990,171
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.070USD
Average target price
6.333USD
Spread / Average Target
+491.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MIST Stock